Triumph's Recap of CBI's Risk-Based Monitoring 2013

October 28, 2013
Duncan Hall

Applied Clinical Trials

Validation - a word we use a lot in this industry. For Triumph Consultancy Services, it is usually a term which we associate with systems development, but on this occasion I'm excited to say I'm talking about validation of our new business division and its ideas.

SPOTLIGHT EVENTRisk-Based Monitoring – Beyond Theory In-Depth ReviewMarch 13, 2014
Cambridge, MassachusettsDownload BrochureRegister

RELATED
- The Emergence of the Centralized Monitor
- Risk-Based Approaches
- ICON Exec Discusses ICONIK MonitoringMore in Risk-Based Monitoring

Validation - a word we use a lot in this industry. For Triumph Consultancy Services, it is usually a term which we associate with systems development, but on this occasion I'm excited to say I'm talking about validation of our new business division and its ideas. This week I was privileged to present at the CBI's Risk-Based Monitoring event in Philadelphia. For the first time since its incorporation, I was presenting as the CEO of Triumph Research Intelligence - a division of Triumph set up with the specific purpose of bringing the best possible Risk-Based Monitoring approach, software platform and services to the life sciences industry.

Having just released our position paper on RBM earlier this week the presentation was a key opportunity to present some of the core messages from that paper to some of the industry’s most forward thinking business leaders. The response was beyond even my most optimistic of expectations. Questions at the end of the presentation ranged from wanting further insight into the statistical methods we employ, the technologies behind the data extraction and transformation from source systems into our quality risk engine, to more company specific needs - how can we integrate this with our existing data capture infrastructure, and how can we use this as a platform for both risk detection and performance management with our own metrics and measurements? All great questions, and all a good indication that RBM is really now at the forefront of most clinical R&D team's agendas.

2013 has been a year of RBM information gathering for the industry and it looks like 2014 is going to be a year of action, learning and further development. There is anticipation and excitement abounding right now, and I think we all realise that RBM is a genuine opportunity to solve some of the quality and cost challenges that are so prevalent in the industry today. Triumph Research Intelligence are well positioned to support the industry on that journey and will continue to invest heavily in our software platform and supporting services to ensure we can support our clients and the industry as a whole to the best of our abilities.

So what did validation mean for us this week? A queue of people waiting for me as I left the podium that day, and beyond that, a further queue of people waiting to talk to us at our exhibition stand. Validation - it feels good to use the term in such a positive light!

Triumph's RBM position paper can be downloaded at www.triumphconsultancy.com

Duncan Hall can be contacted at [email protected]

Related Content:

News | Blogs